Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Idera Pharmaceuticals, Inc.
Scientific Title
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma